RxDoctor Payments Data

Brigitte Shaffer, NP

Family · Houston, MONPI 1407352594

Payments from drug & device makers

$488in general payments, 2019–2025

Across 25 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$83
  • Novo Nordisk$66
  • Exact Sciences$64
  • Braeburn Inc.$43
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • Johnson & Johnson$38
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$47297%
  • Entertainment$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$488 in reported general payments places this provider in the 50th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$2,489
Medicare patients
47
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin109$71,891
OzempicSemaglutide54$57,158
RybelsusSemaglutide46$43,137
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$38,774
Tresiba Flextouch U-200Insulin Degludec29$36,592
JanuviaSitagliptin Phosphate36$30,440
TrulicityDulaglutide20$25,100
EliquisApixaban26$17,444
XareltoRivaroxaban31$17,000
FarxigaDapagliflozin Propanediol22$16,071
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,042
Breo ElliptaFluticasone/Vilanterol23$9,233
SymbicortBudesonide/Formoterol Fumarate29$9,203
EntrestoSacubitril/Valsartan12$8,129
VascepaIcosapent Ethyl16$7,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$66$100,295100 claims
Boehringer IngelheimJardiance$30$71,891109 claims
GSKTrelegy Ellipta, Breo Ellipta$25$48,00778 claims
Johnson & JohnsonXarelto$38$17,00031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,812 family providers in Missouri.

Other family in Houston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →